Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 16/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 10/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 8/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401771 | 0.92 | FGFR1 (0.52) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL4398484 | 0.92 | FGFR1 (0.46) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL4401616 | 0.87 | FGFR1 (0.58) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL4406911 | 0.87 | FGFR1 (0.47) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL4405739 | 0.87 | FGFR1 (0.53) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL4403034 | 0.87 | FGFR1 (0.52) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL4407696 | 0.86 | EGFR (0.50) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL4406745 | 0.84 | FGFR1 (0.50) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL4403338 | 0.84 | FGFR4 (0.46) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL4398577 | 0.83 | FGFR1 (0.55) | FGFR1FGFR4FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549651-B1 | PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS | WARNER LAMBERT CO (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7196090-B2 | Kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| WO-2006038112-A1 | USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS | WARNER-LAMBERT COMPANY LLC (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-1549651-A1 | KINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004011465-A1 | KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | FGFR1 88/4885FGFR4 191/4885FGFR2 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.